• The document is a transcript of the Q1 FY27 Earnings Conference Call held on July 17, 2026, post the announcement of financial results for the quarter ended June 30, 2026.
  • The call was hosted by ICICI Securities Limited and featured management participants Mr. Chintan Shah (Managing Director) and Mr. Ajesh Pillai (Chief Financial Officer).
  • The stated purpose was to discuss the company's financial results and provide a strategic business update.
  • Key financial highlights for Q1 FY27 were disclosed:
  • Operating Revenue: INR 1,671 million (43% YoY growth, 25% QoQ growth)
  • EBITDA: INR 323 million (86% YoY growth, 15% QoQ growth)
  • Segment-wise revenue performance was provided:
  • Phase Transfer Catalysts (PTC): INR 428 million (38% QoQ growth, 47% YoY growth)
  • Electrolyte Salts: INR 63 million (52% QoQ decline, 76% YoY growth)
  • Pharma & Agro Intermediates and Specialty Chemicals (PASC): INR 584 million (63% QoQ growth, 25% YoY growth)
  • Structure Directing Agents (SDA): INR 578 million (10% QoQ growth, 47% YoY growth)
  • Significant strategic updates were provided:
  • New Facility: The Board approved a new greenfield manufacturing facility with an investment of approximately INR 200 crores. A groundbreaking ceremony is scheduled for July 20, 2026. The facility is expected to generate INR 300 crores in revenue at peak utilization (1.2x-1.5x asset turnover).
  • Semiconductor Business: The first commercial-scale batch of a semiconductor chemical was successfully produced and qualified by a customer. This product is used as a key starting raw material for making semiconductors. The company has 5 products in the pipeline for this segment.
  • Guidance: Management reiterated FY27 guidance, expecting 25-30% revenue growth and EBITDA margins of 20-22%. Specific revenue guidance was provided for certain segments:
  • Electrolyte Salts: INR 40-60 crores for FY27.
  • New Pharma Molecules: INR 70-80 crores in FY27, with a potential of INR 200 crores at full utilization.
  • The growth was attributed primarily to volume growth, with price increases being pushed only in the last 40-50 days to pass on higher raw material costs.
  • The company stated that the transcript and related disclosures are available on the stock exchanges (NSE, BSE) and the company's website (www.tatvachintan.com).
  • A standard disclaimer was included, noting that forward-looking statements must be reviewed in conjunction with the risks the company faces.

Additional Notes Section

  • The document is an enclosed transcript submitted as a regulatory filing (Ref. No.: TCPCL/SEC/2026-27/00027) pursuant to Regulation 30 of SEBI LODR.
  • The document includes extensive financial data and forward-looking statements as presented during the earnings call.
  • The company explicitly stated that a detailed disclaimer regarding forward-looking statements was included in the investor presentation shared with the exchanges.